

浅沼博司 北風政史	酸化ストレスと心筋 虚血・再灌流障害	横山光宏 藤田敏郎	酸化ストレスと 心血管病	日本医学 出版	日本	2007	215-223
浅沼博司 朝倉正紀 北風政史	再灌流障害の概念と その対策	吉野秀朗	新一目で見る 循環器病シリーズ —心筋梗塞症	メディカル ビュー社	日本	2007	114-117
浅沼博司 北風政史	心筋虚血	—	日本臨床増刊号 心不全、上	日本臨牀社	日本	2007	321-325
朝倉正紀 浅沼博司 北風政史	虚血性心疾患 —冠血流調節と 心筋虚血	—	内科学 第九版	朝倉書店	日本	2007	487-490
朝倉正紀 北風政史	心不全	—	日本臨床増刊 医薬品副作用学	日本臨牀社	日本	2007	445-449
朝倉正紀 北風政史	心筋梗塞合併時の 薬物療法	熊谷裕生 小室一成 堀内正嗣 森下竜一	高血圧ナビ ゲーター	メディカル レビュー社	日本	2007	288-289
井手友美 筒井裕之	ミトコンドリア活性酸素 生成とシグナル制御	赤池孝章 鈴木敬一郎 内田浩二	活性酸素シグナルと 酸化ストレス	羊土社	日本	2009	38-42
筒井裕之	心不全治療薬・強心薬	山田信博	治療薬イラストレイテ ッド改訂版 一目でわかる薬理作 用と疾患別処方例	羊土社	日本	2009	53-58
筒井裕之	心不全	小川聡	内科学書	中山書店	日本	2009	91-101

絹川真太郎 筒井裕之	心不全	磯部光章 佐々木成	心腎関連の病態理解 と診療	羊土社	日本	2008	50-56
筒井裕之 絹川真太郎	急性心不全	刈尾七臣 筒井裕之	心血管病薬物治療 マニュアル	中山書店	日本	2008	36-44
筒井裕之	慢性心不全	刈尾七臣 筒井裕之	心血管病薬物治療 マニュアル	中山書店	日本	2008	45-52
絹川真太郎 筒井裕之	酸化ストレスと 心不全	横山光宏 藤田敏郎	酸化ストレスと 心血管病	日本医学 出版	日本	2007	209-214
絹川真太郎 筒井裕之	心不全における酸化 ストレスの役割	筒井裕之	別冊・医学のあゆみ 酸化ストレスと心 血管疾患 ー分子機構 の解明から治療への 応用まで	医歯薬 出版	日本	2007	91-95
井手友美 砂川賢二 筒井裕之	レドックス制御に おける Tfam の役割	筒井裕之	別冊・医学のあゆみ 酸化ストレスと心 血管疾患 ー分子機構 の解明から治療への 応用まで	医歯薬 出版	日本	2007	91-95
筒井裕之	心不全	杉本恒明 矢崎義雄	内科学 第九版	朝倉書店	日本	2007	405-413
眞茅みゆき 筒井裕之	食事指導、服薬指導な どの疾病管理プロ グラムは QOL と予後 を改善するか？	三田村秀雄 山科 章 川名正敏 桑島 巖	EBM 循環器疾患の 治療	中外医 学社	日本	2007	336-340

竹端 均 和泉 徹	心不全	和泉 徹	ファーマナビゲータ ーβ遮断薬編	メディカルビ ュー社	日本	2009	60-8
前川恵美 和泉 徹	右心不全の病態生理 一代償から非代償を念 頭において一	和泉 徹	重症心不全の予防と 治療	中外医学社	日本	2009	172-9
成毛 崇 和泉 徹	慢性心不全の治療	和泉 徹	EBM 循環器疾患の 治療 2010-2011	中外医学社	日本	2009	303-5
和泉 徹	心不全を予防する	和泉 徹	日本循環器病予防 学会誌	日本循環器 管理研究 協議会	日本	2009	181-93
竹端 均 和泉 徹	拡張不全とその対応	和泉 徹	心不全診療	メディカル ビュー社	日本	2008	32-37
品川弥人 和泉 徹	IV.心筋疾患 2.拡張型 心筋症	和泉 徹	循環器疾患最新の 治療	南江堂	日本	2008	188-192
東條美奈子 和泉 徹	血管内皮機能と サイトカインの亢進	和泉 徹	睡眠時無呼吸症候群 循環器科医必須知識	メディカル ビュー社	日本	2008	192-199
竹端 均 和泉 徹	ショック	杉本恒明 矢崎義雄	内科学	朝倉書店	日本	2007	413-415
野田千春 和泉 徹	心臓リハビリ テーションへの期待	濱本 紘 野原隆司	心臓リハビリ テーション 昨日・今日・明日	最新医学社	日本	2007	345-347

安村良男	β遮断薬のリバース・リモデリング	萩原俊男 築山久一郎 松崎益徳 島田和幸	β遮断薬のすべて 第3版	先端医学社	日本	2009	305-310
安村良男	若年者心不全に対する心不全の治療薬は、老年者と同じでよいか？βブロッカーは有効か？	小室一成 横井宏佳 山下武志 楽木宏実	2010-2011 EBM 循環器疾患の治療	中外医学社	日本	2009	280-287
安村良男	急性心不全の内科的治療 薬物治療	北風政史	重症心不全の予防と治療	中外医学社	日本	2009	214-215
安村良男	カルペリチド	磯部光章 佐々木成	心腎相関の病態理解と診療	羊土社	日本	2008	272-277
安村良男	急性心不全症例に対して、人工呼吸管理、補助循環を選択する基準は？急性期における強心薬の使い分けは？	小室一成 北風政史	専門医のための薬物療法 Q&A 循環器	中外医学社	日本	2008	233-235
安村良男	PDEⅢ阻害薬	山口 徹	心血管病薬物治療 マニュアル	中山書店	日本	2008	269-271
安村良男	強心薬はまだ必要か？	三田村芳雄 山科 章 川名正敏 桑島 巖	EBM循環器疾患の治療 2008-2009	中外医学社	日本	2007	288-291
安村良男	薬物治療学からみた心不全 —急性心不全治療	北風政史	心不全の診かた ・考えかた	医学書院	日本	2007	107-111

安岡良典 佐々木達哉	急性肺水腫では静注薬をどう使いこなすか		Medicina 45 巻 4 号	医学書院	日本	2008	687-690
佐々木達哉			心不全 診療・管理 のテクニック	医薬 ジャーナル 社	日本	2008	
北田博一 安岡良典 (7人略) 佐々木達哉 (6人略)	総腸骨動静脈瘻により 高拍出性心不全を呈し た一症例		Osaka Heart Club Vol.32 No.7		日本	2008	12-17
安岡良典 佐々木達哉	カテコラミンとイノダイ レーターの使用分けに エビデンスは あるのか?	三田村秀雄 山科 章 川名正敏 桑島 巖	EBM 循環器疾患の 治療 2008-2009	中外 医学社	日本	2007	376-379
安部晴彦 佐々木達哉	アンギオテンシンⅡ 受容体遮断薬(ARB)	猿田享男 細田嗟一 矢崎義雄	循環器科 一慢性心不全薬物 療法の現状と展望	科学 評論社	日本	2007	409-415
白木照夫 河野晋久 斎藤大治	心外膜脂肪腫	矢崎義雄	日本臨床症候群 (Ⅳ)	日本 臨牀社	日本	2008	437-438
宮尾 雄治	V.リスクファクターを バイオマーカーで診る 11.L-6	小川久雄 土師一夫	心血管イベントの リスクファクターと その管理	文光堂	日本	2009	218-221
海北幸一 小川久雄	冠動脈疾患 冠攣縮性狭心症	堀 正二	循環器疾患 最新治療	南江堂	日本	2010	102-104
海北幸一 小川久雄	不安定プラークの破裂 に冠攣縮は関与してい るか	小室一成	EBM 循環器疾患の 治療	中外医学社	日本	2009	56-59

海北幸一 小川久雄	急性冠疾患群の病態 を知る 発生機序	永井良三	最新アプローチ 急性冠症候群	中山書店	日本	2009	22-27
海北幸一 小川久雄	Microvascular angina- その概念と現況 冠微小血管攣縮との 関連性	山口 徹	心臓 Vol.40No.7	日本心臓 財団	日本	2008	.600-603
海北幸一 小川久雄	急性冠症候群における マクロファージの 重要性	田中正広	最新医学 Vol.63.No.8.	最新医学社	日本	2008	20-26
海北幸一 小川久雄	急性冠症候群	松浦三男	総合臨牀 Vo.157.No.2.	永井書店	日本	2008	211-216
海北幸一 小川久雄	冠循環と心筋虚血 障害・心筋梗塞の 病理病態	吉野秀朗	新 目で見る 循環器病シリーズ ー心筋梗塞症	メディカル ビュー社	日本	2007	26-34

雑誌

発表者氏名	論文タイトル名	発表誌名	巻名	頁	出版年
Min K Asakura M (7人略) Asanuma H (1人略) Minamino T (5人略) Furukawa H (1人略) Takashima S (1人略) Kitakaze M	Identification of genes related to heart failure using global gene expression profiling of human failing myocardium	Biochem. Biophys. Res. Commun.	393	55-60	2010
Utsunomiya H (6人略) Kitakaze M	A simple method to predict impaired right ventricular performance and disease severity in chronic pulmonary hypertension using strain rate imaging.	International journal of cardiology		Sep. 9 [Epub ahead of print]	2009
Amaki M (6人略) Kitakaze M	Usefulness of three-dimensional echocardiography in assessing right ventricular function in patients with primary pulmonary hypertension.	Hypertension Res	32	419-422	2009
Sasaki H Asanuma H (5人略) Asakura M (1人略) Minamino T Takashima S (4人略) Kitakaze M	Metformin prevents progression of heart failure in dogs: Role of AMP-activated protein kinase	Circulation	119	2568-2577	2009
Takahama H Minamino T Asanuma H (7人略) Asakura M (1人略) Takashima S (3人略) Kitakaze M	Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats	J Am Coll Cardiol	53	709-717	2009
Tsukamoto O Fujita M (10人略) Minamino T Asakura M (3人略) Kitakaze M	Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure	Journal of the American College of Cardiology	53	2070-2077	2009

Shintani Y Takashima S (2 人略) Kitakaze M	Extracellular protein kinase CK2 is a novel associating protein of neuropilin-1	Biochemical and biophysical research communications.	385	618-623	2009
Wada T, (4 人略) Kitakaze M	A case of coronary artery fistula between a coronary artery and the left atrium following maze procedure	J Am Soc Echocardiogr.	22	e323-326	2009
Asai M (1 人略) Minamino T Asanuma H (5 人略) Asakura M, Takashima S (1 人略) Kitakaze M	PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts	Journal of molecular and cellular cardiology.	46	452-462	2009
Kouzu H (4 人略) Kitakaze M	Noninvasive estimation of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension.	The American journal of cardiology	103	872-876	2009
Fu HY Minamino T (6 人略) Takashima S Hori M Kitakaze M	Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition	Cardiovasc Res	79	600-610	2008
Fujita M Asakura M (4 人略) Asanuma H (6 人略) Kitakaze M	Activation of ecto-5'-nucleotidase in the blood and hearts of patients with chronic heart failure	Journal of Cardiac Failure	14	426-430	2008



Harada K Ogai A Takahashi T Kitakaze M Matsubara H Oh H	Crossveinless-2 controls bone morphogenetic protein signaling during early cardiomyocyte differentiation in P19 cells	The Journal of Biological Chemistry	283	26705-26713	2008
Kato H Takashima S (9人略) Kitakaze M Hori M	Identification of p32 as a novel substrate for ATM in heart	Biochem Biophys Res Commun	366	885-891	2008
Li F Zhao H (5人略) Kitakaze M	Higher mortality in heterozygous neuropilin-1 mice after cardiac pressure overload	Biochem Biophys Res Commun	370	317-321	2008
Yamamoto H Takashima S (8人略) Minamino T (2人略) Kitakaze M	Identification of a novel substrate for TNF $\alpha$ -induced kinase NIAK2	Biochem Biophys Res Commun	365	541-547	2008
Yamano T Nakatani S (8人略) Kitakaze M	Exercise-induced changes of functional mitral regurgitation in asymptomatic or mildly symptomatic patients with idiopathic dilated cardiomyopathy	Am J Cardiol	102	481-485	2008
Seguchi O Takashima S (7人略) Kitakaze M	A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart	J Clin Invest	117	2812-2824	2007
Asanuma H Nakai K (13人略) Kitakaze M	S-nitrosylated and pegylated hemoglobin, a newly developed artificial oxygen carrier, exerts cardioprotection against ischemic hearts	J Mol Cell Cardiol	42	924-930	2007
Kitakaze M Asakura M (7人略) J-WIND Investigators	Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction(J-WIND):two randomised trials	Lancet	370	1483-1493	2007

Tsutsui H Kinugawa S Matsushima S	Mitochondrial oxidative stress and dysfunction in myocardial remodelling	Cardiovasc Res	81	449-456	2009
Naya M Tsukamoto T (7人略) Tsutsui H	Myocardial beta-adrenergic receptor density assessed by 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy.	J Nucl Med	50(2)	220-225	2009
Suga T Okita K (8人略) Tsutsui H	Intramuscular metabolism during low-intensity resistance exercise with blood flow restriction.	J Appl Physiol	106	1119-1124	2009
Matsushima S Kinugawa S (4人略) Tsutsui H	Increased myocardial NAD (P) H oxidase-derived superoxide causes the exacerbation of post-infarct heart failure in type 2 diabetes.	Am J Physiol Heart Circ Physiol	297	409-416	2009
Yokota T Kinugawa S (12人略) Tsutsui H	Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice.	Am J Physiol Heart Circ Physiol	297	1069-1077	2009
Makita N Behr E (13人略) Tsutsui H (3人略)	The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome	J Clin Invest	118	2219-2229	2008
Tsutsumi T Ide T (5人略) Tsutsui H (1人略)	Modulation of the myocardial redox state by vagal nerve stimulation after experimental myocardial infarction	Cardiovasc Res	77	713-721	2008
Hayashi Y Yoshida M (6人略) Tsutsui H (1人略)	Reverse of age-dependent memory impairment and mitochondrial DNA damage in microglia by an overexpression of human mitochondrial transcription factor a in mice	J Neurosci	28	8624-8634	2008

Monden Y Kubota T (6 人略) Tsutsui H (1 人略)	Soluble TNF receptors prevent apoptosis in infiltrating cells and promote ventricular rupture and remodeling after myocardial infarction	Cardiovasc Res	73	794-805	2007
Tsutsui H Tsuchihashi-Makaya M (3 人略) for the JCARE-GENERAL Investigators	Characteristics and outcomes of patients with heart failure in general practices and hospitals -Japanese Cardiac Registry of Heart Failure in General Practice(JCARE-GENERAL)	Circ J	71	449-454	2007
Tsutsui H Matsushima S (7 人略)	Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.	Hypertens Res	30	439-449	2007
Sakai H Urasawa K (4 人略) Tsutsui H	Induction of c-fos mRNA expression by pure pressure overload in cultured cardiac myocytes	Int Heart J	48	359-367	2007
Shimokawa J Yokoshiki H Tsutsui H	Impaired activation of ATP-sensitive K <sup>+</sup> channels in endocardial myocytes from left ventricular hypertrophy	Am J Physiol Heart Circ Physiol	293	H3643 -H3649	2007
Tsukamoto T Morita K (6 人略) Tsutsui H (1 人略)	Decreased Myocardial $\beta$ -Adrenergic Receptor Density in Relation to Increased Sympathetic Tone in Patients with Nonischemic Cardiomyopathy	J Nucl Med	48	1777-1782	2007
Niwano S Wakisaka Y (5 名略) Izumi T	Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function.	Heart	95 (15)	1230-7	2009
Sasayama S Izumi T (4 名略) Ueshima K	Improvement of quality of life with nocturnal oxygen therapy in heart failure patients with central sleep apnea.	Circ J	73(7)	1255-62	2009

Yamaoka-Tojo M Tojo T (6名略) Izumi T	Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia.	Lipids Health Dis	8	41	2009
Ohsaka T Inomata T (6人略) Izumi T	Clinical Impact of adherence to guidelines on the outcome of chronic heart failure in Japan	Int Heart J	49	59-73	2008
Niwano S Fukaya H (6人略) Izumi T	Role of Electrophysiologic Study(EPS)-guided preventive therapy for the management of ventricular tachyarrhythmias in patients with heart failure	Circ J	72	268-273	2008
Nishii M Inomata T (5人略) Izumi T	Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure	J Am Coll Cardiol	51	2329-2335	2008
Niwano S Fukaya H (3人略) Izumi T	Effects of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: spectral analysis of fibrillation waves in the Holter monitoring	Eur Soc Cardiol	9	1209-1215	2007
Shinagawa H Inomata T (6人略) Izumi T	Increased serum bilirubin levels coincident with heart failure decompensation indicate the need for intravenous inotropic agents	Int Heart J	48	195-204	2007
Yoshida Y Shioi T Izumi T	Resveratrol ameliorates experimental autoimmune myocarditis	Circ J	71	397-404	2007
Fujimura M (9人略) Yasumura Y (1人略)	Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.	Acta Cardiol	64	589-595	2009
Iwasaku T (14人略) Yasumura Y	Successful catheter ablation to accessory atrioventricular pathway as cardiac resynchronization therapy in a patients with dilated cardiomyopathy.	Europace	11	online published-ahead of print 6	2009

石津宜丸 廣岡慶治 (9人略) 安村良男	Inoue バルーンによる経皮的肺動脈弁形成術 (PTPV)が著効した成人肺動脈弁狭窄症(PS)の一例	Osaka Heart Club	32	6-10	2008
安村良男	急性心不全の現状 予防的観点からみた 急性期治療とは	内科	99	392-398	2007
安村良男	心不全治療の今昔 :強心薬と利尿薬の位置づけ	治療	89	2083-2086	2007
安村良男	Ca <sup>2+</sup> 感受性増強薬:レボシメンダン	特集心不全 下巻	65 (増刊 号5)	169-172	2007
安村良男	病態からみた薬物療法で心不全を治す	CIRCULATION Up-to-Date	4	55-60	2007
安村良男	慢性心不全におけるβ遮断薬療法	日経メディカル	36	216-219	2007
Sasaki T Noda Y Yasuoka Y (7人略)	Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome	Hypertension Res	31	921-929	2008
Yasuoka Y Morisawa D (6人略) Sasaki T (1人略)	An accordion phenomenon with ST-segment elevation of electrocardiogram and anginal chest pain. -A Case Report	Int J Cardiol		Epub ahead of print	2008
Kunieda T Nakanishi N Matsubara H (11人略) Hishida H	Effects of Long-Acting Beraprost Sodium(TRK-100STP)in Japanese Patients With Pulmonary Arterial Hypertension	International Heart Journal	50	513-529	2009
Morishita T Miyaji K (6人略) Matsubara H	The ratio of both atrial areas reflects the clinical status of patients with pulmonary arterial hypertension.	Journal of Medical Ultrasonics	36	201-226	2009

Kawai Y Hisamatsu K Matsubara H (7人略) Ohe T	Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon	European Heart Journal	30	765-772	2009
松原 広己 宮地 克維	重症肺高血圧症の治療	セラピューティック・リサーチ THERAPEUTIC RESEARCH	30	48-49	2009
宮地 克維 松原 広己	肺動脈性肺高血圧症の新しい治療/ リバースリモデリングの考え方	血栓と循環	17	58-62	2009
Yoshikawa M Nakamura K (3人略) Matsubara H (1人略)	Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis	J Cardiovasc Pharmacol		in press	2009
Akagi S Matsubara H (以下8人略)	Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol	Circ J	72	1142-1146	2008
Sakuma M Demachi J (3人略) Matsubara H (2人略)	Epoprostenol infusion therapy changes angiographic findings of pulmonary arteries in patients with idiopathic pulmonary arterial hypertension	Circ J	72	1147-1151	2008
Date H Kusano KF Matsubara H, (13人略)	Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy	J Am Coll Cardiol	50	523-527	2007
Akagi S Matsubara H (8人略)	Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension	Circ J	71	559-564	2007

Shiraki T Osawa K (7人略)	Incidence and outcomes of out-of-hospital cardiac arrest in the eastern part of Yamaguchi prefecture	International Heart Journal	50	489-500	2009
Shiraki T Kohno K (3人略)	Complete atrioventricular block secondary to lithium therapy	Circ J	72	847-849	2008
白木照夫	血栓溶解、血栓吸引、血管形成術の組み合わせ治療を施行した血栓性上腸間膜動脈虚血の1例	医療	62	285-290	2008
Shiraki T Osawa K Takeuti K (8人略)	A case of acute embolic superior mesenteric ischemia treated with a combination of thrombolysis	thromboaspiration and angioplasty			2007
Matsuzawa Y (7人略) Kaikita K (9人略) Ogawa H	Digital Assessment of Endothelial Function and Ischemic Heart Disease in Women.	J Am Coll Cardiol.		in press	2010
Miura M, Kaikita K (12人略) Ogawa H	Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease.	Thromb Haemost.		in press	2010
Sugamura K (6人略) Kaikita K (2人略) Ogawa H	Activated endocannabinoid system in coronary artery disease and anti-inflammatory effects of cannabinoid 1 receptor blockade on macrophages.	Circulation	119	28-36	2009
Tabata M (9人略) Kaikita K (14人略) Oike Y	Angiotensin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance.	Cell Metab.	10	178-88	2009
Nakayama M Kudoh T Kaikita K (10人略)	Class A macrophage scavenger receptor gene expression levels in peripheral blood mononuclear cells specifically increase in patients with acute coronary syndrome	Atherosclerosis	198	426-433	2008

Honda T Kaikita K (8人略)	Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders	J Mol Cell Cardiol	44	915-926	2008
Fuchigami S Kaikita K (9人略)	Changes in plasma von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina	Thromb Res	122	618-623	2008
Tsujita K Kaikita K (8人略)	Targeted deletion of class A macrophage scavenger receptor increases the risk of cardiac rupture after experimental myocardial infarction	Circulation	115	1904-1911	2007
Matsukawa M Kaikita K (13人略)	Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction	Am J Cardiol	100	758-763	2007
宮尾雄治	心不全例におけるカルベジロール導入クリティカルパスの有用性	呼吸と循環	56	953-956	2008
Kojima S Funahashi T Miyao Y et al	Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction	Atherosclerosis	194	204-213	2007
Kawano H Yoshida T Miyao Y et al	The relationship between endothelial function in the brachial artery and intima plus media thickening of the coronary arteries in patients with chest pain syndrome	Atherosclerosis	195	361-366	2007
藤本和輝 宮尾雄治 村上和憲 ほか	肺塞栓症に対するモンテプラゼの使用経験	Therapeutic Res	28	993-996	2007





## Identification of genes related to heart failure using global gene expression profiling of human failing myocardium

Kyung-Duk Min<sup>a</sup>, Masanori Asakura<sup>a\*</sup>, Yulin Liao<sup>c</sup>, Kenji Nakamaru<sup>d</sup>, Hidetoshi Okazaki<sup>a</sup>, Tomoko Takahashi<sup>d</sup>, Kazunori Fujimoto<sup>d</sup>, Shin Ito<sup>a</sup>, Ayako Takahashi<sup>a</sup>, Hiroshi Asanuma<sup>e</sup>, Satoru Yamazaki<sup>b</sup>, Tetsuo Minamino<sup>g</sup>, Shoji Sanada<sup>a</sup>, Osamu Seguchi<sup>a</sup>, Atsushi Nakano<sup>a</sup>, Yosuke Ando<sup>d</sup>, Toshiaki Otsuka<sup>d</sup>, Hidehiko Furukawa<sup>d</sup>, Tadashi Isomura<sup>f</sup>, Seiji Takashima<sup>g</sup>, Naoki Mochizuki<sup>b</sup>, Masafumi Kitakaze<sup>a</sup>

<sup>a</sup> Department of Cardiovascular Medicine, Osaka, Japan

<sup>b</sup> Research Institute, National Cardiovascular Center, Osaka, Japan

<sup>c</sup> Department of Pathophysiology, Southern Medical University, Guangzhou 510515, China

<sup>d</sup> R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan

<sup>e</sup> Department of Emergency Room Medicine, Kinki University School of Medicine, Sayama, Osaka, Japan

<sup>f</sup> Hayama Heart Center, Hayama, Kanagawa, Japan

<sup>g</sup> Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

### ARTICLE INFO

#### Article history:

Received 12 January 2010

Available online 25 January 2010

#### Keywords:

Gene expression  
cDNA microarray  
Heart failure  
Clinical parameter

### ABSTRACT

Although various management methods have been developed for heart failure, it is necessary to investigate the diagnostic or therapeutic targets of heart failure. Accordingly, we have developed different approaches for managing heart failure by using conventional microarray analyses. We analyzed gene expression profiles of myocardial samples from 12 patients with heart failure and constructed datasets of heart failure-associated genes using clinical parameters such as pulmonary artery pressure (PAP) and ejection fraction (EF). From these 12 genes, we selected four genes with high expression levels in the heart, and examined their novelty by performing a literature-based search. In addition, we included four G-protein-coupled receptor (GPCR)-encoding genes, three enzyme-encoding genes, and one ion-channel protein-encoding gene to identify a drug target for heart failure using *in silico* microarray database. After the *in vitro* functional screening using adenovirus transfections of 12 genes into rat cardiomyocytes, we generated gene-targeting mice of five candidate genes, namely, *MYLK3*, *GPR37L1*, *GPR35*, *MMP23*, and *NBC1*. The results revealed that systolic blood pressure differed significantly between *GPR35*-KO and *GPR35*-WT mice as well as between *GPR37L1*-Tg and *GPR37L1*-KO mice. Further, the heart weight/body weight ratio between *MYLK3*-Tg and *MYLK3*-WT mice and between *GPR37L1*-Tg and *GPR37L1*-KO mice differed significantly. Hence, microarray analysis combined with clinical parameters can be an effective method to identify novel therapeutic targets for the prevention or management of heart failure.

© 2010 Elsevier Inc. All rights reserved.

### Introduction

Heart failure is a multi-factorial condition with increasing prevalence worldwide; further, a significant increase has been observed in the mortality rate and economic impact associated with this condition. In the last 20 years, substantial development of treatment for heart failure, including angiotensin-converting-enzyme inhibitors [1] and beta-blockers [2,3], has greatly improved the

prognosis of the patients with heart failure. However, despite these rapid advancements in the management of heart failure, effective treatment of end-stage heart failure without providing ventricular assistance or heart transplantation is still difficult. Investigation of new and unexplored targets for the prevention or treatment of heart failure is warranted. Global gene expression analysis using microarray technique has been used in the last decade to identify biomarkers or drug targets for heart failure [4–10]. Several gene expression signatures of heart failure have been identified by analyzing independent microarray datasets [11,12]. However, most of these analyses did not consider the severity of heart failure. Because the severity of heart failure may quantitatively reflect the expression levels of genes such as the natriuretic

\* Corresponding author. Address: Department of Research and Development of Clinical Research, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan.

E-mail address: [masakura@hsp.ncvc.go.jp](mailto:masakura@hsp.ncvc.go.jp) (M. Asakura).

peptide-encoding gene, expression analysis combined with the severity of heart failure could be an appropriate method to identify heart failure-related genes. However, microarray analysis of genes expressed in failing myocardium while considering the severity of heart failure has not yet been reported.

Hence, we investigated the genes whose expression level correlated with clinical parameters such as pulmonary artery pressure (PAP), left ventricular ejection fraction (EF), and brain natriuretic peptide (BNP) mRNA level. Using this approach, we identified cardiac myosin light chain kinase as a novel heart failure-related gene [13]. Here, we describe newly identified several genes whose expression correlated with clinical parameters and additional genes encoding G-protein-coupled receptor genes (GPCRs), other enzymes and ion-channel proteins, and performed the functional analysis of these heart failure-related genes. This novel strategy involving the use of clinical parameters might find potential applications for the identification of disease-associated genes that could not be detected using conventional microarray techniques.

## Materials and methods

**Patient characteristics.** We recruited 12 patients (11 males and 1 female) with heart failure and obtained written informed consent from them. The patients were diagnosed with severe chronic heart failure due to various cardiac diseases such as dilated cardiomyopathy and myocardial infarction [13]. The average age of patients was  $55 \pm 13$  years. The plasma level of BNP, which is the best marker for the severity of heart failure, ranged from 80 to 2710 pg/ml. The mean PAP measured using a Swan-Ganz catheter 1–4 weeks before the operation varied between 16 and 59 mmHg. The average of EF determined by echocardiography on the day before the operation was  $32.5\% \pm 12.4\%$ .

**Microarray analysis and subsequent in silico functional analysis.** RNA was extracted from myocardium samples of 12 heart failure patients who had undergone either Batista or Dor surgeries. RNA samples of non-failing hearts were purchased from Biochain, Inc. Complementary RNA (cRNA) was prepared from RNA samples and hybridized to HG-U95 Affymetrix GeneChip (Affymetrix, US). The expression data were analyzed using Microarray Analysis Suite version 5.0 software. Among all the genes detected on the microarray, we selected the genes whose expression was significantly different in the failing and non-failing myocardial samples ( $p < 0.005$ ). From these genes, we selected genes whose expression was correlated with PAP, EF, and BNP mRNA level, with 0.7 being the cutoff value of the correlation coefficient. The values of PAP, EF, and BNP mRNA level used for the correlation analysis were normalized to their median during the measurements. Subsequently, the functional analysis of datasets was performed using Ingenuity Pathway Analysis (Ingenuity® Systems; www.ingenuity.com), and the biological functions most significant to the dataset were identified.

**Cell culture.** Cardiomyocytes were harvested before the experiments from 2- to 3-day-old neonatal rats and cultured as described in previous studies [14]. Briefly, primary cardiomyocytes isolated from neonatal rats were grown in Dulbecco's modified Eagle medium/F12 (Gibco) supplemented with 10% fetal calf serum for 72 h, and then cultured in a serum-free condition for 24 h.

**Adenovirus generation and transfection.** Adenovirus constructs encoding the genes of interest were generated using the ViraPower Adenoviral Expression System (Invitrogen, US) according to the manufacturer's method. Adenovirus vectors were transfected to cultured cardiomyocytes for 12 h according to the published protocol.

**In vitro functional analysis of genes.** Cultured rat cardiomyocytes were infected by adenovirus vectors. After 24 h, hypertrophic

reaction, cell viability, and cellular morphology were assessed. Hypertrophic reaction was determined by estimating the incorporation of [<sup>3</sup>H]phenylalanine. In brief, [<sup>3</sup>H]phenylalanine was added to the culture medium at the final concentration of 0.1  $\mu$ Ci/ml, and the cells were incubated for an additional 24 h. Then, the incorporation of [<sup>3</sup>H]phenylalanine was determined by counting the radioactivity of each sample with a liquid scintillation counter. The viability of cardiomyocytes was evaluated by the Alamar blue assay according to the manufacturer's method. The morphology of cardiomyocytes was evaluated 24 h after adenovirus transfections.

**Generation of transgenic and knockout mice.** To generate transgenic mice, open reading frame of each gene, namely, *Mylk3*, *Gpr3711*, or *Nbc1* was amplified from mouse cDNA by PCR, with Sal I site linker on each end, and cloned into Sal I site of alpha-MHC clone 26 vector. Then the DNAs used in the microinjections were released from the vector by digestion with NotI and were microinjected into fertilized eggs of mouse. Founder mice were identified by PCR analysis with appropriate primers. To develop *Gpr3711* knockout mice, the targeting vector was assembled to replace the exon 1 and 2 by neomycin selection cassette resulting in the absence of *Gpr3711* protein. W9.5 ES cells were electroporated with linearized targeting vector. ES cell clones with successful homologous recombination was determined by the PCR and subsequent direct sequence. From these targeted ES cells, the chimera mice were bred to C57 BL/6 females to generated F1 and F2 offsprings were obtained. The *Gpr3711* null mice were determined by PCR genotyping of F2 offsprings. The knockout mice of *Gpr35* and *Mmp23* (the mouse ortholog of MMP23B) were purchased from Deltagen, Inc. (California, US).


**Invasive blood pressure measurement.** The phenotype of the gene-targeted mice was examined. Before sacrificing the mice, their hemodynamic parameters were evaluated. The mice were anesthetized and ventilated, and a Millar catheter was inserted via right carotid artery. The left-ventricular systolic and end-diastolic pressures were measured. Then, the mice were sacrificed and the weight of the whole body and heart was determined.

**Statistical analysis.** Unpaired Student's *t*-test was used for comparing the two groups. Results are expressed as means  $\pm$  SEM, and *p* value less than 0.05 was considered statistically significant.

## Results

### Identification of heart failure-related genes by expression analysis using clinical parameters

We performed microarray analysis of the genes expressed in failing myocardium obtained from 12 patients with heart failure and the genes expressed in non-failing myocardium from two normal objects whose characteristics were reported in the previous study [13]. Although all patients were diagnosed with chronic heart failure, the plasma BNP level, which is an index of the severity of heart failure, ranged from 80 to 2710 pg/ml, suggesting that the severity of heart failure varied extensively among the patients. This marked difference in the severity of heart failure reflects the fact that the gene expression patterns in the 12 patients were not uniform, as shown in Fig. 1A. Thus, we analyzed gene expression profiles of failing myocardium using clinical parameters representing the severity of heart failure. We identified 166 and 194 genes whose expressions were correlated with PAP and BNP mRNA level, respectively (Fig. 1B and Supplementary Tables S1, S2). Among these, 49 genes correlated with both PAP and BNP mRNA level (Fig. 1C). The expression of only two genes, namely, *FMO2* and *LMAN1L*, correlated with the EF. We investigated the functional categories of these genes by performing Ingenuity Pathway Analysis. The number of genes in each group, functional categories, and



**Fig. 1.** The gene expression profile of human failing or non-failing myocardium. Gene expression levels of myocardial samples from 12 patients with severe heart failure and from two normals were analyzed using microarray. (A) Heat maps showing the genes with differential expression between the 12 failing myocardial samples and the two non-failing myocardial samples. Red color indicates upregulated gene expression. Green color indicates downregulated gene expression. Arrows indicate non-failing samples. (B) Expression profile of positively or negatively correlated genes to pulmonary artery pressure (PAP) or brain natriuretic peptide (BNP) mRNA level ( $r > 0.7$ ). (C) Venn diagram of genes correlated with PAP, BNP, and ejection fraction.

**Table 1**  
Datasets of genes whose expressions were correlated to clinical parameters.

	PAP	EF	BNP mRNA level
<i>Positive correlation</i>			
Number	124	1	175
Function	Cardiovascular system development and function Cell death	-	Cardiovascular system development and function Cell cycle
Representative genes	<i>ARNT, MYOCD, SMARCA4</i> <i>BGN, CFLAR, EEF2, MTPN</i>	<i>LMAN1L</i>	<i>BTG1, NPPA, NPPB, SERPINF1</i> <i>CKS1B, DDR2, FCGR2B, FN1</i>
<i>Negative correlation</i>			
Number	42	1	19
Function	Skeletal and muscular system development and function Cellular assembly and organization	-	Skeletal and muscular system development and function Cellular assembly and organization
Representative genes	<i>PIK3R1, PRKAR1A, SLMAP</i> <i>C19ORF20, RAB9A, SYNGAP1, TTN</i>	<i>FMO2</i>	<i>ACTC1, RBBP4, TTN</i>

The function of gene sets was analyzed by Ingenuity Pathway Analysis.  
PAP, pulmonary artery pressure; EF, ejection fraction; BNP, brain natriuretic peptide.

representative genes are shown in Table 1. Interestingly, both gene sets correlated positively with PAP and BNP mRNA level were most associated with the same functional category of "cardiovascular system development and function", although the included genes were different. Similarly, the gene sets correlated negatively with both PAP and BNP mRNA level had most association with common functional categories of "skeletal and muscular system development and function" and "cellular assembly and organization".

#### Selection of 12 genes for in vitro screening

Among the genes selected using clinical parameters, we selected those genes that showed high expression levels in the heart by performing microarray analysis. On the basis of their novelty determined by a literature-based search, we selected four genes for further investigation (Table 2). Concurrently, to identify possible drug targets, we included four orphan GPCRs and four additional genes (three enzyme-encoding genes and one ion-channel protein-encoding gene) in the further analysis. The *RHOQ* and

*STK38* genes were selected based on their correlation with BNP mRNA level and PAP, respectively. *GPR161* and *NBC1* were selected owing to their high expression level in the heart. *GPR37L1*, *GPR35*, *F2RL2*, and *MMP23B* were selected because of their high expression level in the heart, and their association with the cardiac diseases-related genes listed in the database was determined by *in silico* analysis.

#### Functional analysis of genes on the basis of adenovirus-mediated overexpression of proteins in neonatal rat cardiomyocytes

To determine which of the selected genes were associated with the physiological functions of the heart, we first generated adenovirus vectors for each gene listed in Table 2 and transfected these vectors into neonatal rat cardiomyocytes. Next, we evaluated the hypertrophic reaction, viability, and morphology of the transfected cardiomyocytes. Among the 12 selected genes, three adenovirus-mediated genes decreased the incorporation of [ $^3$ H]phenylalanine in neonatal rat cardiomyocytes (Table 2); the expression of one

**Table 2**  
*In vitro* functional screening of the 12 candidate genes.

Probe set ID	Gene symbol	Gene name	Criteria for selection	p value	[ <sup>3</sup> H]PA intake	Fluorescence of Alamar blue	Cellular morphology
<i>Genes relevant to clinical parameters</i>							
75678_at	MYLK3	Myosin light chain kinase 3	Correlation with PAP (r = 0.792)	0.00262	No change	No change	Spiking
49333_at	XPR1	Xenotropic and polytropic retrovirus receptor	Correlation with PAP (r = 0.765), GPCR, change in CHF	0.00045	No change	No change	No change
38435_at	PRDX4	Peroxisiredoxin 4	Correlation with BNP (r = 0.863)	0.00024	Increased	Decreased	No change
45314_at	SMOC2	SPARC related modular calcium binding 2	Correlation with both PAP and BNP (r = 0.715 and 0.758, respectively)	0.00444	No change	No change	No change
<i>Genes encoding orphan GPCRs</i>							
35544_at	GPR37L1	G-protein-coupled receptor 37 like 1	Orphan GPCR, downregulated in CVD	>0.005	Decreased	Decreased	Apoptosis
31700_at	GPR35	G-protein-coupled receptor 35	Orphan GPCR, upregulated in MI	0.00216	Decreased	Decreased	Hypertrophy
45204_at	F2RL2	Coagulation factor II (thrombin) receptor-like 2	GPCR, change in CVD	>0.005	Increased	No change	No change
40299_at	GPR161	G-protein-coupled receptor 161	GPCR, expression in heart	>0.005	Decreased	Decreased	No change
<i>Genes encoding interesting enzymes or ion-channels</i>							
38950_at	MMP23B	Matrix metalloproteinase 23B	Family of MMP, change in CHF	>0.005	No change	Decreased	No change
35285_at	NBC1	Na <sup>+</sup> -HCO <sub>3</sub> <sup>-</sup> cotransporter 1	Expression in heart	>0.005	No change	Decreased	No change
87788_at	RHOQ	Ras homolog gene family, member Q	Expression in DCM, correlation with BNP (r = 0.711)	>0.005	No change	No change	No change
78801_at	STK38	Serine/threonine kinase 38	Kinase activity, correlation with PAP (r = 0.736)	>0.005	No change	No change	No change

PAP, pulmonary artery pressure; GPCR, G-protein-coupled receptor; CHF, congestive heart failure; BNP, brain natriuretic peptide; CVD, cardiovascular disease; MI, myocardial infarction; DCM, dilated cardiomyopathy; PA, phenylalanine. *p* value indicates the significance of the difference between the gene expression level of failing and non-failing myocardium.

gene promoted [<sup>3</sup>H]phenylalanine incorporation; and the overexpression of six genes lowered the viability of cardiomyocytes, which was evaluated by Alamar blue assay. We also evaluated the phenotype of transfected cardiomyocytes. Unlike control cells, MYLK3-adenovirus-transfected cardiomyocytes were spike shaped. The overexpression of GPR37L1 induced apoptosis of cardiomyocytes. The transfection of NBC1-adenoviral vectors modified the beating rate of cardiomyocytes (data not shown). Then, we analyzed each gene that encoded a distinct cardiomyocyte phenotype by developing gene-targeted mouse models.

#### *In vivo* analysis using transgenic and knockout mice

To study the *in vivo* role of the selected genes, we developed genetically modified mice: three transgenic (Tg) mice for *Mylk3*, *Gpr37L1*, or *Nbc1* and three knockout (KO) mice for *Gpr37L1*, *Gpr35*, or *Mmp23*. We estimated hemodynamic parameters using Miller catheter and the heart weight (HW)/body weight (BW). As shown in Fig. 2A, we found that the blood pressure of *Gpr37L1*-KO mice was significantly higher than that of *Gpr37L1*-Tg mice by 61.7 mmHg (*p* < 0.01). Further, the blood pressure of *Gpr35*-KO mice was higher than that of wild type (WT) littermate by 37.5 mmHg (*p* < 0.01). Overexpression with or knockout of *Mylk3*, *Mmp23*, or *Nbc1* did not result in a significant change in the systolic blood pressure. The HW/BW of *Mylk3*-Tg mice was lower than that of *Mylk3*-WT mice (Fig. 2B). The HW/BW was higher in *Gpr37L1*-KO mice than in *Gpr37L1*-Tg mice. The HW/BW in mice with *Nbc1*, *Gpr35*, or *Mmp23* manipulations did not show any difference. These data showed that modification of *Gpr37L1*, *Gpr35*, or *Mylk3* can produce a distinct cardiovascular phenotype *in vivo*.

#### Discussion

The present study identified heart failure-related genes using a novel strategy that was different from the conventional microarray analysis approach. Firstly, we constructed global gene expression profiles to analyze the gene expression in 12 human samples of failing myocardium and two samples of non-failing myocardium. Secondly, we prepared datasets of heart failure-related genes asso-

ciated with the severity of heart failure; this approach is unique to our study and has not been published before. Thirdly, we selected four genes from these datasets by microarray analysis and a literature-based search. We also included four orphan GPCR genes and four other genes with high expression in the heart as possible drug targets for heart failure treatment. Fourthly, we screened the *in vitro* functions of these 12 genes by achieving adenovirus-mediated overexpression of these genes in rat cardiomyocytes. Finally, we generated gene-targeted mouse models of the five selected genes and screened the *in vivo* functions of these genes. Our novel strategy using a microarray analysis revealed three potential targets, namely, MYLK3, GPR37L1, and GPR35 for diagnosing and managing heart failure.

End-stage heart failure caused by a variety of cardiovascular diseases including hypertension, cardiomyopathy, and ischemic heart disease features a common phenotype of reduced cardiac function and dilated cardiac chamber. This result strongly suggested the existence of common genes during the development of heart failure, including the genes encoding natriuretic peptides. To identify novel diagnostic or therapeutic targets for heart failure, such as natriuretic peptides, several microarray analyses of genes expressed in failing myocardium have been performed in the last decade by comparing the gene expression levels between different pairs of samples, such as non-failing versus failing hearts [4–6], failing hearts before versus after placement of left-ventricular assisting device [7,8], hypertrophic versus failing hearts [9], ischemic versus non-ischemic hearts [10]. However, the severity of heart failure is not fixed, but varies from mild to severe heart failure in these studies. To identify the therapeutic targets for heart failure effectively, we believe that it is important to consider the severity of heart failure with microarray data analysis. In this study, we prepared new datasets of heart failure-associated genes that were selected from gene expression profiles of 12 human failing myocardial samples using clinical parameters. A number of genes were associated with PAP, which is an index for the severity of heart failure, whereas only two genes correlated with EF, which is an index for cardiac contractility. This result implies that the stress caused to the heart, and not the ability of cardiac contraction, regulates gene expression in heart failure. We also selected heart failure-related genes whose expression correlated to